Tissue regeneration aims to restore function to diseased or damaged tissue by delivering living elements which provide the necessary physical and biological environment for the body to heal itself. Healing is stimulated via the interplay between cells and cell communicators (cytokines & growth factors) both of which are delivered within a biological scaffold (or extra-cellular matrix).
Early efforts in our field of tissue regeneration (also called Tissue Engineering) were driven, in part, to overcome the shortage of donor organs suitable for transplantation. Today, living three dimensional tissue regeneration constructs are FDA approved and available on demand for multiple therapeutic applications.
Over the last twenty years, our field has transitioned from visionary science fiction, into exciting, proven science, and has recently become a successful commercial reality.
When Organogenesis was founded in the early 80's, the company consisted of a few scientists. Today, we are the world's leading tissue regeneration company, with approximately 200 staff members worldwide - and growing.
Organogenesis has pioneered the development of novel products based on advances in cell biology and tissue regeneration. In addition, we have launched the industry's first commercial successful products.
To sustain our momentum, we aim to attract and retain the most talented people who are dedicated to our mission of bringing the medical marvel of tissue regeneration products to patients worldwide and standardizing their use in everyday medical care.
Geoff MacKay: President and Chief Executive Officer
Organogenesis Inc.
150 Dan Road
Canton, Massachusetts 02021
United States
Telephone: +1 (781) 575-0775
Organogenesis Switzerland GmbH
Baarerstrasse 2
CH-6304 Zug
Switzerland
Telephone: +41 41 727 67 89
